CING Company Profile and Key Details

CING has shown sold momentum, gaining 21.15% over the past week and 59.46% over the past quarter, though year-to-date performance is up 35.94%. Short-term trend indicators are bearishly aligned (SMA20 2.37%, SMA50 20.92%, SMA200 47.08%). The stock’s 14-day RSI is 56.19 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.06% below its high and over 102.81% above its low. Average 10-day trading volume of 436.43 thousand shares is below the 3-month average of 502.77 thousand, indicating normal recent market interest.

Cingulate Inc. generated EPS of -$5.29 over the past year. Five-year average earnings growth is 40.0%. Wall Street analysts project EPS growth of 60.26% annually over the next five years. The latest quarter delivered EPS of -$0.95. The next quarter is forecast at -$0.63. Next year's EPS is expected at $51.52. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $14.00. The high target offers 1180.99% upside. The low target suggests 189.26% downside. The mean target is $37.25. This offers 669.63% upside. Cingulate Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 14, 2026, missed forecasts by 79.25%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include -90.54% in March 27, 2025.

Cingulate Inc. has 5.41 million shares outstanding. The public float is 5.40 million shares, elevated short interest at 3.70% of float. This equals 195.40 thousand shares. The short ratio is 1.19 days. Institutional investors hold 5.36% of the float. Insiders own 1.81%. GIVENS GREGG WM holds 154.32 thousand shares, Hargroves Thomas Jeffrey has 77.82 thousand shares and Werth Peter J. has 15.56 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Cingulate Inc. (NASDAQ:CING) closed at $4.84 USD, losing -$0.25 (-4.91%) from the previous close of $5.09. The stock is currently mid-range between its 52-week high and low $3.16 and $11.89. With a market capitalization of about $27.13 million, Cingulate Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.92). Key stats such as the average daily volume over the past year has been around 568.23 thousand shares, in line with its 52-week average. Headquartered in Kansas City, KS, Cingulate Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shane J. Schaffer, the company employs approximately 13 people and listed since December 08, 2021. Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD).

Cingulate Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.40. This means the shares are trading above this model’s fair value.

Cingulate Inc. (NASDAQ:CING) shares are up 35.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cingulate Inc. trading at a premium to the broader market with a P/E of -0.97. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.87, suggesting 413.84% upside. Our AI forecast model points to short-term strength (9.09% over two weeks), a medium-term fall (-5.37% over three months), and a longer-term gain (22.11% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cingulate Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.09%, with price expected at $5.28 by July 22, 2026, within a range of $4.91 to $5.61 3-Month Outlook: Projected fall of -5.37%, reaching $4.58 by October 06, 2026, with a range of $4.14 to $5.00. 1-Year Outlook: Projected gain of 22.11%, with price at $5.91 by July 08, 2027, within a range of $2.24 to $6.99.

Cingulate Inc. trades at a P/E ratio of -0.97, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.41 suggesting the stock is closer to book value. The P/FCF stands at -1.39, also below market averages.